Berberine protects against gefitinib-induced liver injury by inhibiting the HMGB1/TLR4/NF-κB pathway

BackgroundGefitinib (GEF), a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for non-small cell lung cancer (NSCLC), is frequently associated with drug-induced liver injury (DILI), thereby limiting its clinical application. This study aimed to evaluate the he...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Qiongyin Zhang, Na Li, Xue Ma, Yue Qiu, Chao Li, Ya Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Subjects:	gefitinib berberine drug-induced liver injury (DILI) HMGB1/TLR4/NF-κB hepatoprotection
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1645634/full